Who Exports Imipenem from India — 140 Suppliers Behind a $33.3M Market
India's imipenem export market is supplied by 140 active exporters who collectively shipped $33.3M across 803 shipments. VENUS REMEDIES LIMITED leads with a 40.6% market share, followed by SUN PHARMACEUTICAL INDUSTRIES LIMITED and SWISS PARENTERALS LIMITED. The top 5 suppliers together control 79.7% of total export value, reflecting a concentrated market structure.
Top Imipenem Exporters from India — Ranked by Export Value
VENUS REMEDIES LIMITED is the leading imipenem exporter from India, holding a 40.6% share of the $33.3M market across 803 shipments from 140 exporters. The top 5 suppliers — VENUS REMEDIES LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, SWISS PARENTERALS LIMITED, SUN PHARMACEUTICAL INDUSTRIES LTD, PROTECH BIO SYSTEMS PRIVATE LIMITED — collectively control 79.7% of total export value, indicating a highly concentrated market. Individual shares are: VENUS REMEDIES LIMITED (40.6%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (24.9%), SWISS PARENTERALS LIMITED (6.3%), SUN PHARMACEUTICAL INDUSTRIES LTD (4.0%), PROTECH BIO SYSTEMS PRIVATE LIMITED (4.0%).
Top Imipenem Exporters from India
Ranked by export value · 140 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | VENUS REMEDIES LIMITED SENSIMITINA 500MG (IMIPENEM/CILASTATIN 5SENSIMITINA 500MG (IMIPENEM / CILASTATINIMIPENEM AND CILASTATIN 500MG | $13.5M | 27 | 40.6% |
| 2 | SUN PHARMACEUTICAL INDUSTRIES LIMITED IMANEN 500 MGPANTIN 500 MG IMIPENEM & CILASTATIN FORIMIPENEM+CIL BASICS-S INJ 500MG PACK: 10 | $8.3M | 17 | 24.9% |
| 3 | SWISS PARENTERALS LIMITED IMANEN 500 MGCIMI IMIPENEM AND CILASTATIN FOR INJECTION USP 1GMBACQURE INJECTION 500 MG PACK:SP 1 VIAL | $2.1M | 6 | 6.3% |
| 4 | SUN PHARMACEUTICAL INDUSTRIES LTD IMANEN 500 MGPANTIN 500 MG IMIPENEM & CILASTATIN FORIMIPENEM+CIL BASICS-S INJ 500MG PACK: 10 | $1.3M | 8 | 4.0% |
| 5 | PROTECH BIO SYSTEMS PRIVATE LIMITED IMIPENEM & CILASTATIN 500MG+500MG,N-1 CLHARMLESS MEDICINES-IMIPENEM &CILASTATIN | $1.3M | 2 | 4.0% |
| 6 | M J BIOPHARM PRIVATE LIMITED SENSIMITINA 500MG (IMIPENEM/CILASTATIN 5SENSIMITINA 500MG (IMIPENEM / CILASTATINIMIPENEM AND CILASTATIN 500MG | $713.1K | 2 | 2.1% |
| 7 | VEXXA LIFESCIENCES PVT. LTD. PANTIN 500 MG IMIPENEM & CILASTATIN FOR | $348.2K | 3 | 1.0% |
| 8 | JODAS EXPOIM PRIVATE LIMITED | $326.9K | 1 | 1.0% |
| 9 | KWALITY PHARMACEUTICALS LIMITED PANTIN 500 MG IMIPENEM & CILASTATIN FOR | $324.4K | 4 | 1.0% |
| 10 | MARKSANS PHARMA LIMITED | $236.5K | 1 | 0.7% |
| 11 | M. J. BIOPHARM PRIVATE LIMITED PANTIN 500 MG IMIPENEM & CILASTATIN FOR | $228.9K | 3 | 0.7% |
| 12 | VIDA LABORATORIES PRIVATE LIMITED PANTIN 500 MG IMIPENEM & CILASTATIN FOR | $200.9K | 7 | 0.6% |
| 13 | BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED IMPRACID 500MG- NOS | $172.2K | 1 | 0.5% |
| 14 | VENUS REMEDIES LTD SENSIMITINA 500MG (IMIPENEM/CILASTATIN 5SENSIMITINA 500MG (IMIPENEM / CILASTATINIMIPENEM AND CILASTATIN 500MG | $168.1K | 5 | 0.5% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Imipenem exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Venus Remedies Limited | QIDP designation for VRP- | Yes | Yes | Not verified | Received QIDP designation from FDA for VRP-034 in April 2025. |
| Sun Pharmaceutical Industries Limited | Approved | Yes | Yes | Not verified | FDA-approved manufacturer with WHO and EU GMP certifications. |
| Swiss Parenterals Limited | Not Listed | Yes | No | Not verified | WHO GMP certified; no FDA listing found. |
| Baxter Pharmaceuticals India Private Limited | Approved | Yes | Yes | Not verified | FDA-approved manufacturer with WHO and EU GMP certifications. |
| Jodas Expoim Private Limited | Not Listed | Yes | No | Not verified | WHO GMP certified; no FDA listing found. |
| Kwality Pharmaceuticals Limited | Not Listed | Yes | No | Not verified | WHO GMP certified; no FDA listing found. |
| Marksans Pharma Limited | Approved | Yes | Yes | Not verified | FDA-approved manufacturer with WHO and EU GMP certifications. |
| M J Biopharm Private Limited | Not Listed | Yes | No | Not verified | WHO GMP certified; no FDA listing found. |
TransData Nexus reviewed the regulatory standing of 8 leading Imipenem exporters from India. 3 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 4 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Imipenem sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of active pharmaceutical ingredients (APIs). The city hosts numerous manufacturing facilities that contribute significantly to India's API output. Companies such as Granules India Limited, headquartered in Hyderabad, specialize in the manufacture and sale of APIs, pharmaceutical formulation intermediates, and finished dosage forms. Their product portfolio includes essential drugs like Paracetamol, Metformin, and Guaifenesin.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. This region is home to prominent companies like Alembic Pharmaceuticals, headquartered in Vadodara. Alembic Pharmaceuticals manufactures and markets a wide range of pharmaceutical products, including APIs and formulations, with a presence in the macrolide anti-infective drug segment. Their operations encompass manufacturing facilities in Gujarat and research and development centers in India and the United States.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt in Maharashtra serves as a critical export gateway for pharmaceutical products. This region's strategic location and well-developed infrastructure facilitate the export of pharmaceuticals to global markets. Maharashtra leads the country with the highest number of pharmaceutical clusters, totaling 40, underscoring its pivotal role in India's pharmaceutical exports.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, largely due to favorable tax incentives. This area hosts numerous pharmaceutical units, contributing to the region's economic growth and employment. Himachal Pradesh is home to 555 pharmaceutical units, reflecting its importance in the industry.
5Sourcing Recommendations
- Diversify Supplier Base: To mitigate risks associated with supply chain disruptions, consider sourcing Imipenem from multiple manufacturers across different pharmaceutical clusters.
- Evaluate Supplier Credentials: Prioritize suppliers with certifications from recognized regulatory bodies such as the US FDA, EMA, or WHO to ensure compliance with international quality standards.
- Assess Export Capabilities: Given the significant export activities from regions like Maharashtra, evaluate suppliers' experience and infrastructure in handling international shipments to ensure timely delivery.
- Monitor Regulatory Compliance: Regularly review suppliers' adherence to regulatory requirements and quality control measures to maintain product integrity and compliance with global standards.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Imipenem exporters from India
Sun Pharmaceutical Industries Limited — Sun Pharma acquires 60% stake in Vivaldis Health and Foods
In June 2023, Sun Pharmaceutical Industries Limited completed the acquisition of a 60% shareholding in Vivaldis Health and Foods Private Limited for ₹1,433.2 million. - IMPACT: This acquisition is expected to enhance Sun Pharma's product portfolio, potentially influencing its Imipenem export capabilities.
Impact: This acquisition is expected to enhance Sun Pharma's product portfolio, potentially influencing its Imipenem export capabilities.
Common Questions — Imipenem Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which imipenem supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, VENUS REMEDIES LIMITED leads with 194 recorded shipments worth $13.5M. SUN PHARMACEUTICAL INDUSTRIES LIMITED (119 shipments) and SWISS PARENTERALS LIMITED (9 shipments) are also established high-volume exporters.
Q How many imipenem manufacturers are there in India?
India has 140 active imipenem exporters with a combined export market of $33.3M across 803 shipments to 94 countries. The top 5 suppliers hold 79.7% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for imipenem from India?
Average FOB unit price: $4.71 per unit, ranging from $0.08 to $119.08. Average shipment value: $41.5K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 140 verified Indian exporters of Imipenem ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 803 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 94 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
803 Verified Shipments
140 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists